Superiority of an Intranasal Corticosteroid Compared With an Oral Antihistamine in the As-Needed Treatment of Seasonal Allergic Rhinitis

Kaszuba, Scott M.; Baroody, Fuad M.; deTineo, Marcy; Haney, Lauran; Blair, Christopher; Naclerio, Robert M.

doi:10.1001/archinte.161.21.2581

Cited by 103 publications

(64 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of INS therapy conducted in 2009 demonstrated efficacy in alleviating ocular symptoms, supporting earlier findings on the utility of this drug class as an ocular allergy therapy, including comparative research that indicates that INS provide equal or greater relief of ocular allergy symptoms as compared with intranasal [50] or oral antihistamines [40,[51][52][53]. Data published in the past year are reviewed below.…”

Section: Intranasal Corticosteroidssupporting

confidence: 54%

Allergic Conjunctivitis and the Impact of Allergic Rhinitis

Bielory¹

2010

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Although nasal allergy has been prominent in allergy research, ocular allergy is increasingly recognized as a distinct symptom complex that imposes its own disease burden and reduction in patients' quality of life. In the past year, knowledge of the relationships between allergic conjunctivitis and allergic rhinitis has increased. Allergic conjunctivitis is highly prevalent and has a close epidemiologic relationship with allergic rhinitis. Both conditions also exhibit similar pathophysiologic mechanisms. Pathways of communication are thought to increase the likelihood of an inflammatory reaction at both sites following allergen exposure of nasal or ocular tissue. Clinical trials of intranasal therapies have demonstrated efficacy in allergic conjunctivitis and rhinitis. Newer intranasal steroids decrease ocular symptoms, potentially achieving efficacy by suppressing the naso-ocular reflex, downregulation of inflammatory cell expression, or restoration of nasolacrimal duct patency. Proposed pathophysiologic interactions between allergic rhinitis and ocular allergy underscore the need for therapies with efficacy in both symptom sets.

show abstract

Section: Intranasal Corticosteroidssupporting

confidence: 54%

Allergic Conjunctivitis and the Impact of Allergic Rhinitis

Bielory¹

2010

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…When the medications prescribed for SR patients in other clinics before admission to our clinic and those suggested by our clinic are compared, statistically significant differences and important therapeutic defects were noted. For example, the rate of nasal steroid usage, which is the drug of choice for SR [30], was only 13.1% before admission. In addition, these patients were mostly prescribed antihistamines as a monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Seasonal Rhinitis, Clinical Characteristics and Risk Factors for Asthma

Bozkurt

Karakaya²,

Kalyoncu³

2005

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The aim was to determine the clinical characteristics of patients with seasonal rhinitis (SR) and to disclose differences in the treatment of SR between an adult allergy clinic and other clinics over time. Methods: A retrospective study was conducted based on clinical records of 774 out of 955 patients diagnosed with SR in an adult allergy clinic between 1 January 1991 and 31 December 2003. Results: The mean age of the patients was 29.1 ± 9.29 years and 62.7% were female. The most common major complaints of the patients were nasal symptoms in 82.3%. The mean duration of the disease was 6.76 ± 6.8 years. The patients were symptomatic with a mean of 3.5 ± 1.7 months a year, mostly during the period between April and July. Skin prick tests were positive in 685 patients (90.3%), where the most common sensitivity was against timothy grass (85.1%). The most common accompanying allergic diseases were food hypersensitivity in 14%, bronchial asthma in 13.4%, and drug allergy and/or intolerance in 9.6%. Although the use of specific immunotherapy and short-acting sedative antihistamines decreased over time, the use of nasal steroids and long-acting nonsedative antihistamines tended to increase before admission to our clinic. Older age (OR: 1.77, 95% CI: 1.06–2.94), presence of familial atopy (OR: 1.72, 95% CI: 1.04–2.85), respiratory symptoms (OR: 2.10, 95% CI: 1.75–2.50), ocular symptoms (OR: 0.77, 95% CI: 0.61–0.98) and metal allergy (OR: 0.25, 95% CI: 0.07–0.89) were associated with the development of asthma in patients with SR. Conclusion: SR lasts approximately 3.5 months and the main cause in Ankara, Turkey is grass pollen sensitivity. Patients with any other allergic conditions make up 39.8% of the patients. SR patients are referred to allergy clinics quite late, which might be due to SR not being considered as a serious disease.

show abstract

“…The RQLQ has been used in several trials to assess the effect of intranasal glucocorticosteroids (1085,(1089)(1090)(1091)(1092)(1093)(1094), oral H 1 -antihistamines in seasonal (1095)(1096)(1097), perennial (1077,1078) and PER (1066,1067,1098), the combination of intranasal glucocorticosteroids and oral H 1 -antihistamines (1099), leukotriene receptor antagonists (1100, 1101), allergen immunotherapy in pollinosis (1102)(1103)(1104), omalizumab, an anti-IgE monoclonal antibody (768,1105), allergen avoidance (1106) and homeopathy (1107). Studies have also been performed in children (1108).…”

Section: Evolution Of Qol During Interventionsmentioning

confidence: 99%